Rigel Pharmaceuticals, Inc. (RIGL)
Rigel Pharmaceuticals: Realizing The Promise Of Its Acquired Pipeline Agents
Rigel Pharmaceuticals has shown significant growth, particularly from the acquisition of pralsetinib, leading to a 46% improvement in stock valuation since April. Rigel's pipeline includes three approved drugs and promising candidates like R289 and ocadusertib, with notable advancements in clinical trials and Fast Track designation. Financially, RIGL has turned profitable with a $12.4 million net income in the latest quarter, but high debt and potential cash flow challenges loom.
How Much Upside is Left in Rigel (RIGL)? Wall Street Analysts Think 28.28%
The average of price targets set by Wall Street analysts indicates a potential upside of 28.3% in Rigel (RIGL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Rigel Pharmaceuticals, Inc. (RIGL) Q3 2024 Earnings Call Transcript
Rigel Pharmaceuticals, Inc. (RIGL) Q3 2024 Earnings Call Transcript
Rigel Pharmaceuticals (RIGL) Q3 Earnings and Revenues Top Estimates
Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to loss of $0.30 per share a year ago.
Rigel Pharmaceuticals: Looking For More Growth
Rigel Pharmaceuticals' strategic acquisitions of GAVRETO and REZLIDHIA, along with strong TAVALISSE sales, position the company for significant growth and potential profitability. Despite historical negative EPS, Rigel has shown upward revenue trends, with recent earnings revealing a 37.03% year-over-year revenue increase and a reduced net loss. Growth opportunities include expanding product labels, advancing the R289 program, and leveraging partnerships, particularly in the growing hematology and oncology markets.
Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic Partnerships
Rigel Pharmaceuticals has surged 50.1% since my previous article, driven by successful execution, innovative portfolio, strategic partnerships, and pipeline progress. RIGL's FDA-approved drugs, Tavalisse, Rezlidhia, and Gavreto, are key revenue drivers. They have experienced significant sales growth and promise future contributions, particularly from Gavreto. The company's international collaborations and ongoing clinical trials, especially for olutasidenib, indicate potential for new revenue streams and competitive IP in hematology and oncology.
Rigel (RIGL) Surges 19.7%: Is This an Indication of Further Gains?
Rigel (RIGL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Rigel Pharmaceuticals, Inc. (RIGL) Q2 2024 Earnings Call Transcript
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Ray Furey - EVP, General Counsel and Corporate Secretary Raul Rodriguez - President and CEO Dave Santos - Chief Commercial Officer Lisa Rojkjaer - Chief Medical Officer Dean Schorno - CFO Conference Call Participants Yigal Nochomovitz - Citi Kristen Kluska - Cantor Joe Pantginis - H.C. Wainwright Operator Greetings and welcome to Rigel Pharmaceutical's Financial Conference Call for the Second Quarter 2024.
Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates
Rigel Pharmaceuticals (RIGL) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.40 per share a year ago.
Rigel Pharmaceuticals (RIGL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Rigel (RIGL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential
Rigel Pharmaceuticals focuses on innovative therapeutics for hematological conditions and cancers, with FDA-approved products Tavalisse, Rezlidhia, and Gavreto targeting specific diseases. RIGL's pipeline also includes promising drug candidates like R289, targeting lower-risk myelodysplastic syndromes and other kinase-related diseases. Gavreto, recently acquired by RIGL, targets RET fusion-positive NSCLC and thyroid cancer, with significant potential for revenue growth.
